Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)
NCT04296942 · National Cancer Institute (NCI) · PHASE1 · terminated · last registry update 2022-01-11 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “One participant was accrued, and the study was stopped due to new safety data from the company for M7824 and slow accrual.” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HDAC1 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-06-30Results posted on the registry: Syndax Pharmaceuticals, Entinostat + Aromatase Inhibitor (AI) Therapy (NCT00828854)
- 2022-06-06Also stopped (terminated): Syndax Pharmaceuticals, SNDX-275 (NCT00754312)
- 2022-05-03Results posted on the registry: University of Maryland, Baltimore, entinostat + anastrozole (NCT01234532)
- 2022-05-03Also stopped (terminated): University of Maryland, Baltimore, entinostat + anastrozole (NCT01234532)
- 2021-11-16Results posted on the registry: National Cancer Institute (NCI), Entinostat + Exemestane (NCT02115282)
- 2021-05-18Also stopped (withdrawn): Pamela Munster, Abexinostat Tosylate + Fulvestrant (NCT04498520)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision